Lonza, Agennix begin manufacturing deal
BASEL, Switzerland—Lonza and Agennix AG have announced a development and manufacturing deal for the production of Agennix's first-in-class oral Dendritic Cell Mediated Immunotherapy, talactoferrin, which is currently in Phase III testing for the treatment of non-small cell lung cancer. Per the terms of the agreement, Lonza will produce commercial material at its microbial manufacturing facility. The deal is the first step in seeking approval for Lonza to become a second manufacturer of talactoferrin after its initial commercial launch.
"In anticipation of positive Phase III data and a potential product approval, it is important that we have more than one manufacturer in place to ensure we can meet anticipated commercial demand and that we have security of supply," Dr. Rajesh Malik, chief medical officer and management board member of Agennix, said in a statement.